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Duchenne muscular dystrophy (DMD) is a chronic,
complex, genetic childhood disease affecting boys, where
sufferers typically die in their 20s. DMD is caused by
mutations in the dystrophin gene and trials are currently
underway with exon skipping, a therapy which works by
patching the mutation thereby allowing production of a
functional gene. The dystrophin gene contains 79 exons
and mutations can be found in one or more exons.
Treatment must be targeted to the specific exon which
is at fault and each one therefore requires a different
exon skipping chemistry. The success of trials with exon
skipping will present patients and physicians with the
possibility of a personalised medicine and with that, a
number of ethical issues. Firstly, equity and harm by
omission. Exons for the most common mutations will
be tested first and researchers assert that conforming to
the existing regulatory pathway for every exon, it will
not be cost effective. This raises the real possibility of
those children with rarer exons being denied a poten-
tially lifesaving treatment. Secondly, if therapies are
developed for the rarer mutations, risk and uncertainty
become more difficult to assess. In some cases a boy
may be his own control in a RCT and the boundaries
between experiment and therapy become blurred.
Thirdly, justice and minimum entitlement: given that
minimum entitlement in this case is likely to be very
expensive (the comparable myozome therapy costs
$300,000 per person, per year), the distribution of lim-
ited health resources throughout a population is once
again under scrutiny. This paper aims to anticipate
these ethical issues with a view to helping researchers,
clinicians, regulators and patient organisations to find
ways to ensure that the development of these life-saving
therapies progresses.
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Ethical issues
The success of trials with exon skipping will bring the possibility of 
personalised medicine aimed at small sub-sets of boys with DMD.
Harm by omission
Within current regulations each exon would be considered a new drug 
which must undergo rigorous testing.  This would not be cost effective 
and raises the possibility of those children with rarer exons being denied 
a potentially lifesaving treatment (2).
Children with DMD are disadvantaged due to the rarity of their condition, 
its life-limiting nature and from the lack of effective therapies.  The 
precautionary approach to research this vulnerability requires can also be 
a further disadvantage. The protection afforded to these children needs to 
be balanced against the disadvantage of delaying research leading to 
effective treatment thereby harming by omission.
Boundaries between clinical care and experiment
• If therapies are developed for the rarer mutations the number of patients 
available to test a certain mutation become fewer
• A single person may be his own control in a trial
• Boundaries between experiment and therapy become blurred
• Therapy in such cases should be considered as empirical treatment 
rather than experimental trial
“the community feels fragmented based on mutations, as if, for 
some boys, there is less hope than for others”
Pat Furlong, patient/parent representative
Stage 1: PRESYMPTOMATIC Stage 2: EARLY AMBULATORY Stage 3: LATE AMBULATORY Stage 4: EARLY NON-AMBULATORY                  Stage 5: LATE NON-AMBULATORY
DMD and personalised medicine
The definition of personalised medicine should not be confined to 
identifying sub-populations whose response to a particular drug or 
treatment can be determined by their genotype but can also be taken to 
mean the tailoring of a medicine for sub-sets of patients with certain 
genetic characteristics, as discussed in this poster.
Duchenne muscular dystrophy (DMD)
• An incurable rare disease
• One of the most common childhood genetic disorders, affecting boys 
primarily
• A fatal and devastating, progressive, muscle wasting disease
• Death from heart failure or respiratory problems typically in the twenties
• Social and emotional effects of the disease for families can be very 
burdensome
Gene mutation
DMD is caused by mutations in the gene that encodes for dystrophin –
the protein that builds muscle.  Dystrophin is the largest gene in the body, 
containing 79 exons and most mutations consist of a deletion of one or 
more of these exons.  One of the most promising therapies in 
development is exon skipping where treatment is targeted to a specific 
exon and each different mutation requires a different chemical „patch‟ to 
treat the disease.
There would need to be 30 different exon skipping chemistries to treat the 
majority of patients.  Exons for the most common mutations will be tested 
first and trials for two exons are in progress or planned.
Top 10 exons in DMD (1)
Some points to note with research in small populations
• Any deviation from randomised controlled trials should be rigorously 
justified
• Patients should be made fully aware of the increased uncertainty and 
the risk/benefit balance
• Power of the study should be maximised by using a range of 
methodologies and exploiting historical data
• Good science is the basis of good ethics
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Exon number Approximate % of patients
51 13.0%
45 8.1%
53 7.7%
44 6.2%
46 4.3%
52 4.1%
50 4.0%
43 3.8%
6 & 7 3.0%
8 2.3%
Reimbursement and non-abandonment
Exon skipping is likely to be an expensive therapy.  Although the EC has 
introduced orphan drugs legislation designed to assure that „patients 
suffering from rare conditions should be entitled to the same quality of 
treatment as other patients‟, orphan drug availability varies from country 
to country (3, 4).
Most would uphold the idea that the community has a moral obligation 
not to abandon those born with rarer mutations.  We can see that orphan 
drugs incentives have been successful in helping to develop new 
therapies and the regulatory authorities are open to exploring new ways 
of regulating personalised medicines.  To have significant resources 
assigned to a therapy which will be available to some patients within a 
single disease and not to others appears to be unjust.
